Previous Article | Next Article ![]()
Infection and Immunity, December 2000, p. 6618-6623, Vol. 68, No. 12
Malaria Vaccine Development Unit, Laboratory of Parasitic
Diseases, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, Rockville, Maryland
208521; Department of Parasitology and
Immunology, University of Tokushima School of Medicine, Tokushima
770-8503,2 and Department of Molecular
Parasitology, Ehime University School of Medicine, Shigenobu-cho, Ehime
791-0295,3 Japan; Division of Parasitic
Diseases and Animal Resources Branch, Scientific Resources Program,
National Center for Infectious Diseases, Centers for Disease Control
and Prevention, Chamblee, Georgia 303414; and
Department of Entomology, Armed Forces Research Institute
of Medical Sciences, Phayathai, Bangkok 10400, Thailand5
Received 21 July 2000/Returned for modification 6 September
2000/Accepted 16 September 2000
Transmission-blocking vaccines are one strategy for controlling
malaria, whereby sexual-stage parasites are inhibited from infecting
mosquitoes by human antibodies. To evaluate whether the recently cloned
Plasmodium vivax proteins Pvs25 and Pvs28 are candidates
for a transmission-blocking vaccine, the molecules were expressed
in yeast as secreted recombinant proteins. Mice vaccinated with these
proteins adsorbed to aluminum hydroxide developed strong antibody
responses against the immunogens, although for Pvs28, this response was
genetically restricted. Antisera against both recombinant Pvs25 and
Pvs28 recognized the corresponding molecules expressed by cultured
sexual-stage parasites isolated from patients with P. vivax
malaria. The development of malaria parasites in mosquitoes was
completely inhibited when these antisera were ingested with the
infected blood meal. Pvs25 and Pvs28, expressed in
Saccharomyces cerevisiae, are as yet the only fully
characterized transmission-blocking vaccine candidates
against P. vivax that induce such a potent antiparasite response.
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28
Completely Block the Ability of Plasmodium vivax To
Infect Mosquitoes
*
Corresponding author. Mailing address: Malaria Vaccine
Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 12441 Parklawn Dr., Rockville, MD 20852. Phone: (301) 435-2968. Fax:
(301) 435-6725. E-mail: astowers{at}niaid.nih.gov.
Present address: Viral and Vaccine Research, Merck Research Labs,
West Point, PA 19486.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|